Antares Pharma, Inc. (NASDAQ:ATRS) Director Leonard S. Jacob sold 230,000 shares of the stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $4.05, for a total value of $931,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Antares Pharma, Inc. (NASDAQ ATRS) traded down 0.51% on Wednesday, hitting $3.94. The stock had a trading volume of 2,335,230 shares. Antares Pharma, Inc. has a 1-year low of $1.41 and a 1-year high of $4.09. The company’s market cap is $616.24 million. The stock has a 50 day moving average price of $3.19 and a 200 day moving average price of $2.99.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%. The firm had revenue of $13.42 million for the quarter, compared to analysts’ expectations of $12.99 million. On average, equities research analysts expect that Antares Pharma, Inc. will post ($0.11) EPS for the current fiscal year.

WARNING: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/11/leonard-s-jacob-sells-230000-shares-of-antares-pharma-inc-atrs-stock.html.

Several institutional investors and hedge funds have recently modified their holdings of ATRS. State Street Corp boosted its position in shares of Antares Pharma by 2,682.1% in the 2nd quarter. State Street Corp now owns 2,027,650 shares of the specialty pharmaceutical company’s stock worth $6,530,000 after purchasing an additional 1,954,769 shares in the last quarter. Northern Trust Corp boosted its position in shares of Antares Pharma by 478.1% in the 2nd quarter. Northern Trust Corp now owns 1,654,266 shares of the specialty pharmaceutical company’s stock worth $5,327,000 after purchasing an additional 1,368,131 shares in the last quarter. Rubric Capital Management LP boosted its position in shares of Antares Pharma by 34.4% in the 2nd quarter. Rubric Capital Management LP now owns 3,188,600 shares of the specialty pharmaceutical company’s stock worth $10,267,000 after purchasing an additional 816,630 shares in the last quarter. Morgan Stanley boosted its position in shares of Antares Pharma by 153.3% in the 1st quarter. Morgan Stanley now owns 996,113 shares of the specialty pharmaceutical company’s stock worth $2,829,000 after purchasing an additional 602,834 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Antares Pharma by 10.1% in the 2nd quarter. Vanguard Group Inc. now owns 6,186,232 shares of the specialty pharmaceutical company’s stock worth $19,920,000 after purchasing an additional 567,144 shares in the last quarter. 36.77% of the stock is currently owned by hedge funds and other institutional investors.

ATRS has been the topic of several recent research reports. Vetr upgraded Antares Pharma from a “hold” rating to a “buy” rating and set a $3.30 price target on the stock in a report on Wednesday, July 5th. Chardan Capital initiated coverage on Antares Pharma in a report on Friday, June 23rd. They issued a “buy” rating and a $5.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Antares Pharma in a report on Friday, June 23rd. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Antares Pharma in a report on Friday, September 8th. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $4.34.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Insider Buying and Selling by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.